Nathan
NathanGPT
Chat Videos Regulatory Strategy About Nathan
En
Nathan Qin
Nathan Qin
Managing Partner, qinnovativ medtech
AI Medtech Advisor
Medtech Strategy Available 24/7

The Future of Medtech
Strategy, Available 24/7

#FDAReguatory #CardiacAI #CrossBorder
Chat with Nathan
Medtech Insights FDA Update
De Novo vs 510(k): How to Choose the Right FDA Pathway for Your AI Medical Device
Cross-Border Market Entry
China NMPA Registration: Timeline Realities vs. What Consultants Tell You
Cardiac AI Clinical Evidence
CCTA Analysis Algorithms Face Tougher FDA Clinical Evidence Bar in 2025 Guidance Update
Recommended View all
Nathan Qin — Medtech Strategist
Medtech Strategy
Breakthrough Device Designation Could Slash Your Time-to-Market by 40% — Here's How to Qualify
Regulatory FDA Pathways
EU MDR Transition: Why Over 60% of Medtech Startups Are Underprepared for CE Recertification
🇪🇺
Cardiac AI Clinical Data
AI-Guided CCTA Interpretation Shows 34% Reduction in Unnecessary Cath Lab Referrals in New Study
🫀
Fundraising VC Strategy
What Medtech VCs Actually Want to See Before Writing a Series A Check in 2025
💰
Market Entry Go-to-Market
Former J&J Medical Designer Breaks Down the Hospital Procurement Process Founders Always Get Wrong
🏥
Nathan Qin
Nathan Qin
Managing Partner, qinnovativ medtech · AI Digital Twin

Nathan Qin is a global medtech strategist with 15+ years spanning J&J, Boston Scientific, and Siemens Healthineers. Executive Board at CASIS (Cardiac Simulation & Imaging Software), Kellogg MBA, and Industrial Design graduate of Umeå Institute of Design (Sweden).

NathanGPT is his AI digital twin — trained on his expertise in FDA pathways, NMPA registration, EU MDR, cardiac AI, cross-border commercialization, and medtech fundraising. Available 24/7 to give you the same caliber of advice, instantly.

Chat with NathanGPT Book a Call with Nathan Connect on LinkedIn